Roche And Proximagen SIGN VAP-1 Inflammatory Deal
This article was originally published in Scrip
Executive Summary
Roche and Proximagen Ltd., a wholly owned UK subsidiary of Upsher-Smith laboratories, Inc. have announced a worldwide agreement for the further development of PRX700, an oral small molecule inhibitor vascular adhesion protein 1 (VAP-1), which is currently in phase II clinical development.